{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:36:16Z","timestamp":1791725776208,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ASLAN Pharmaceuticals Pte Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40259-024-00685-y","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T14:53:59Z","timestamp":1729004039000},"page":"821-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Eblasakimab, an Anti-IL\u201113R\u03b11 Antibody, Reduces Atopy-Associated Serum Biomarkers in Moderate\u2011to\u2011Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct04090229","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7518-1757","authenticated-orcid":false,"given":"Ferda","family":"Cevikbas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2201-8850","authenticated-orcid":false,"given":"Alison","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9222-192X","authenticated-orcid":false,"given":"Karen A.","family":"Veverka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"2","key":"685_CR1","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0738-081X(02)00361-9","volume":"21","author":"K Kang","year":"2003","unstructured":"Kang K, Stevens SR. Pathophysiology of atopic dermatitis. Clin Dermatol. 2003;21(2):116\u201321.","journal-title":"Clin Dermatol"},{"key":"685_CR2","doi-asserted-by":"crossref","unstructured":"David Boothe W, Tarbox JA, Tarbox MB. Atopic dermatitis: pathophysiology. Manag atopic Dermat. 2017; p. 21-37.","DOI":"10.1007\/978-3-319-64804-0_3"},{"key":"685_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107830","volume":"224","author":"X Yang","year":"2021","unstructured":"Yang X, Kambe N, Takimoto-Ito R, Kabashima K. Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials. Pharmacol Ther. 2021;224: 107830.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"685_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1080\/1744666X.2021.1940962","volume":"17","author":"C Dubin","year":"2021","unstructured":"Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835\u201352.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"685_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1042\/BJ20121819","volume":"451","author":"NT Redpath","year":"2013","unstructured":"Redpath NT, Xu Y, Wilson NJ, et al. Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor \u03b11. Biochem J. 2013;451(2):165\u201375.","journal-title":"Biochem J"},{"issue":"4","key":"685_CR6","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/j.jaci.2021.01.013","volume":"147","author":"Y Renert-Yuval","year":"2021","unstructured":"Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis\u2014a review on behalf of the International Eczema Council. J Allergy Clin Immunol. 2021;147(4):1174\u201390.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"685_CR7","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/ACI.0000000000000198","volume":"15","author":"J Thijs","year":"2015","unstructured":"Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15(5):453\u201360.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"685_CR8","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s13555-024-01193-1","volume":"14","author":"F Libon","year":"2024","unstructured":"Libon F, Caron J, Nikkels AF. Biomarkers in Atopic Dermatitis. Dermatol Ther (Heidelb). 2024;14:1729\u201338. https:\/\/doi.org\/10.1007\/s13555-024-01193-1.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"685_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2199-7-45","volume":"7","author":"K Liddiard","year":"2006","unstructured":"Liddiard K, Welch JS, Lozach J, Heinz S, Glass CK, Greaves DR. Interleukin-4 induction of the CC chemokine TARC (CCL17) in murine macrophages is mediated by multiple STAT6 sites in the TARC gene promoter. BMC Mol Biol. 2006;7(1):45. https:\/\/doi.org\/10.1186\/1471-2199-7-45.","journal-title":"BMC Mol Biol"},{"issue":"3","key":"685_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mai.2001.113237","volume":"107","author":"T Kakinuma","year":"2001","unstructured":"Kakinuma T, Nakamura K, Wakugawa M, et al. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity. J Allergy Clin Immunol. 2001;107(3):535\u201341. https:\/\/doi.org\/10.1067\/mai.2001.113237.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"685_CR11","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/cia2.12225","volume":"5","author":"K Kogawa","year":"2022","unstructured":"Kogawa K, Minakawa S, Matsuzaki Y, et al. Correlation between lactate dehydrogenase and other laboratory data in patients with atopic dermatitis. J Cutan Immunol Allergy. 2022;5(4):133\u20135. https:\/\/doi.org\/10.1002\/cia2.12225.","journal-title":"J Cutan Immunol Allergy."},{"issue":"3","key":"685_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2021.100519","volume":"14","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ J. 2021;14(3): 100519. https:\/\/doi.org\/10.1016\/j.waojou.2021.100519.","journal-title":"World Allergy Organ J"},{"key":"685_CR13","doi-asserted-by":"publisher","unstructured":"Pellefigues C. IgE autoreactivity in atopic dermatitis: paving the road for autoimmune diseases? Antibodies (Basel, Switzerland). 2020. https:\/\/doi.org\/10.3390\/antib9030047","DOI":"10.3390\/antib9030047"},{"issue":"7","key":"685_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021;51(7):915\u201331. https:\/\/doi.org\/10.1111\/cea.13954.","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"685_CR15","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S0091-6749(97)70276-8","volume":"100","author":"J Punnonen","year":"1997","unstructured":"Punnonen J, Yssel H, de Vries J. The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+ or CD8+ T cells. J Allergy Clin Immunol. 1997;100(6):792\u2013801.","journal-title":"J Allergy Clin Immunol"},{"key":"685_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2024.1365544","volume":"15","author":"T Hagino","year":"2024","unstructured":"Hagino T, Hamada R, Yoshida M, Fujimoto E, Saeki H, Kanda N. Total eosinophil count as a biomarker for therapeutic effects of upadacitinib in atopic dermatitis over 48 weeks. Front Immunol. 2024;15:1\u201310. https:\/\/doi.org\/10.3389\/fimmu.2024.1365544.","journal-title":"Front Immunol"},{"key":"685_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109677","volume":"253","author":"F Cevikbas","year":"2023","unstructured":"Cevikbas F, Ward A, Firth C, Veverka K. Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers. Clin Immunol. 2023;253: 109677. https:\/\/doi.org\/10.1016\/j.clim.2023.109677.","journal-title":"Clin Immunol"},{"issue":"3","key":"685_CR18","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.jaad.2023.10.026","volume":"90","author":"K Veverka","year":"2024","unstructured":"Veverka K, Thng S, Silverberg J, et al. Safety and efficacy of eblasakimab, an IL-13R\u03b11 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: a phase 1b, multiple-ascending dose study. J Am Acad Dermatol. 2024;90(3):504\u201311. https:\/\/doi.org\/10.1016\/j.jaad.2023.10.026.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"685_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ijd.15183","volume":"60","author":"T Yamauchi","year":"2021","unstructured":"Yamauchi T, Sasaki S, Lee ES, et al. Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis. Int J Dermatol. 2021;60(2):190\u20135.","journal-title":"Int J Dermatol"},{"issue":"3","key":"685_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/cia2.12280","volume":"6","author":"C Fujiwara","year":"2023","unstructured":"Fujiwara C, Uchiyama A, Inoue Y, Ishikawa M, Motegi S. Real-world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2-year experience. J Cutan Immunol Allergy. 2023;6(3):88\u201393. https:\/\/doi.org\/10.1002\/cia2.12280.","journal-title":"J Cutan Immunol Allergy."},{"issue":"6","key":"685_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","volume":"21","author":"S Ferreira","year":"2020","unstructured":"Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib. Am J Clin Dermatol. 2020;21(6):783\u201398.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"685_CR22","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1111\/all.16108","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024;79(1):1560\u201372.","journal-title":"Allergy"},{"issue":"9","key":"685_CR23","doi-asserted-by":"publisher","first-page":"B19","DOI":"10.1016\/j.jid.2021.07.123","volume":"141","author":"L Lee","year":"2021","unstructured":"Lee L, Hajireen H, Ward A, Firth C. A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor. J Invest Dermatol. 2021;141(9):B19. https:\/\/doi.org\/10.1016\/j.jid.2021.07.123.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"685_CR24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","volume":"371","author":"LA Beck","year":"2014","unstructured":"Beck LA, Tha\u00e7i D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1314768.","journal-title":"N Engl J Med"},{"issue":"2","key":"685_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","volume":"1","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacother. 2010;1(2):100\u20137.","journal-title":"J Pharmacol Pharmacother"},{"issue":"5","key":"685_CR26","first-page":"419","volume":"136","author":"J Laurent","year":"1985","unstructured":"Laurent J, Noirot C, Ansquer JC, Laurent G, Kestenbaum S, Lagrue G. How to define the normal level of serum IgE in adults? Ann Med Interne (Paris). 1985;136(5):419\u201322.","journal-title":"Ann Med Interne (Paris)"},{"key":"685_CR27","unstructured":"Farhana A, Lappin SL. Biochemistry, lactate dehydrogenase. In: StatPearls [Internet]. StatPearls Publishing; 2022."},{"issue":"1","key":"685_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","volume":"137","author":"AM Drucker","year":"2017","unstructured":"Drucker AM, Wang AR, Li W-Q, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26\u201330. https:\/\/doi.org\/10.1016\/j.jid.2016.07.012.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"685_CR29","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1007\/s13555-022-00819-6","volume":"12","author":"AN Fasseeh","year":"2022","unstructured":"Fasseeh AN, Elezbawy B, Korra N, et al. Burden of atopic dermatitis in adults and adolescents: a systematic literature review. Dermatol Ther (Heidelb). 2022;12(12):2653\u201368. https:\/\/doi.org\/10.1007\/s13555-022-00819-6.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"685_CR30","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s13555-022-00737-7","volume":"12","author":"E-B Haddad","year":"2022","unstructured":"Haddad E-B, Cyr SL, Arima K, McDonald RA, Levit NA, Nestle FO. Current and emerging strategies to inhibit type 2 inflammation in atopic dermatitis. Dermatol Ther (Heidelb). 2022;12(7):1501\u201333. https:\/\/doi.org\/10.1007\/s13555-022-00737-7.","journal-title":"Dermatol Ther (Heidelb)."},{"key":"685_CR31","unstructured":"Veverka KA, Menezes J, Thng STG, Simpson E. Eblasakimab Improves Itch and Sleep Loss in Adult Patients with Moderate-to-Severe Atopic Dermatitis in a Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study. Portland, OR; 2022. http:\/\/aslanpharma.com\/app\/uploads\/2022\/09\/EADV-PRO-poster_FINAL.pdf. Accessed 07 Nov 2022"},{"issue":"16","key":"685_CR32","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3390\/jcm11164639","volume":"11","author":"S Mastraftsi","year":"2022","unstructured":"Mastraftsi S, Vrioni G, Bakakis M, et al. Atopic dermatitis: striving for reliable biomarkers. J Clin Med. 2022;11(16):4639.","journal-title":"J Clin Med"},{"key":"685_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13601-020-00338-7","volume":"10","author":"FMS Badloe","year":"2020","unstructured":"Badloe FMS, De Vriese S, Coolens K, et al. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy. 2020;10:34. https:\/\/doi.org\/10.1186\/s13601-020-00338-7.","journal-title":"Clin Transl Allergy."},{"issue":"4","key":"685_CR34","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.1111\/ajd.13719","volume":"62","author":"M Mizuno","year":"2021","unstructured":"Mizuno M, Horiguchi G, Teramukai S, et al. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab. Australas J Dermatol. 2021;62(4):e504\u20139. https:\/\/doi.org\/10.1111\/ajd.13719.","journal-title":"Australas J Dermatol"},{"issue":"1","key":"685_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-016-0170-1","volume":"7","author":"M Megna","year":"2017","unstructured":"Megna M, Napolitano M, Patruno C, et al. Systemic treatment of adult atopic dermatitis: a review. Dermatol Ther (Heidelb). 2017;7(1):1\u201323. https:\/\/doi.org\/10.1007\/s13555-016-0170-1.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"685_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","volume":"143","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155\u201372. https:\/\/doi.org\/10.1016\/j.jaci.2018.08.022.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"685_CR37","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jdcr.2020.08.036","volume":"6","author":"F Bawany","year":"2020","unstructured":"Bawany F, Franco AI, Beck LA. Dupilumab: one therapy to treat multiple atopic diseases. JAAD case reports. 2020;6(11):1150\u20132. https:\/\/doi.org\/10.1016\/j.jdcr.2020.08.036.","journal-title":"JAAD case reports."},{"key":"685_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910381","author":"L Salvati","year":"2021","unstructured":"Salvati L, Cosmi L, Annunziato F. From emollients to biologicals: targeting atopic dermatitis. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910381.","journal-title":"Int J Mol Sci"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00685-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00685-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:04:58Z","timestamp":1730487898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00685-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["685"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00685-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"25 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by ASLAN Pharmaceuticals Pte Ltd, Singapore and San Mateo, CA USA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Drs Cevikbas and Veverka are former employees and Dr Ward was a consultant of ASLAN Pharmaceuticals Pte Ltd at the time of submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Datasets related to this article can be provided upon request by the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The conduct of the study was guided by the principles of the Declaration of Helsinki and in compliance with International Council for Harmonization and Good Clinical Practice guidelines; and was approved by the Domain Specific Review Board (DSRB) in Singapore, Bellberry Human Research Ethics Committee in South Australia, and Advarra Center for IRB Intelligence (CIRBI) in USA.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all patients prior to participation in the study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Conceptualization and study design: AW; Data acquisition, analysis, and interpretation: FC, AW, KV; Supervision: KV; Writing \u2013 Original draft preparation: KV, FC; Writing \u2013 review and editing: KV, FC, AW. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}